In particular, given the Tregs and PD1 control by p75NTR and NGF, NGF pathway inhibition would result in immune tolerance induction, thus challenging the use tout-court of TrkA inhibitors to dampen tumor growth. The gene discussed is NGFR; the disease is neoplasm.